Current Research and Scholarly Interests
Working with the Infectious Diseases Research Collaboration in Uganda, we study how naturally acquired immunity to malaria develops in infants, young children, and pregnant women, and how malaria prevention shapes this process. In birth cohorts in Eastern Uganda, we have reported that infant sex (PMID 33272281) and sickle cell trait (PMID 33738485) modify malaria immune phenotypes in infancy.
After repeated Plasmodium falciparum (Pf) infections, children gain the ability to tolerate low-level parasitemia without symptoms. We identified an atypical CD56-negative NK cell subset that expands with repeated exposure, performs antibody-dependent cellular cytotoxicity, and correlates with protection, but is rapidly lost when exposure stops (PMID 36696483). Using EpiTOF, a single-cell epigenetic profiling technique developed at Stanford, we found that repeated Pf exposure induces epigenetic changes in innate immune cells that regulate inflammation and predict clinical immunity (PMID 39161730). In human tonsil and spleen organoids, Vδ2+ γδ T cells clonally expand and become cytotoxic after Pf exposure, a pattern also seen in tonsils of infected Ugandan children (PMID 41961880). To further define these processes, we are longitudinally profiling innate and adaptive immune responses in young children across single and repeated infections using multiomic assessments of host immunity and computational approaches.
We hypothesize that clinical tolerance to Pf is driven in part by malaria-specific type 1 regulatory (Tr1) CD4+ T cells. Using longitudinal single-cell RNA and T cell receptor sequencing, we tracked individual CD4+ T cell clones through repeated Pf infections, and found that Tr1 cells make up nearly 90% of Pf-specific CD4+ T cells, persist as long-lived memory cells, and mount faithful recall responses after reinfection (PMID 40279404). We then identified CXCR6 and CD127 as markers that enrich for Tr1 cells. CXCR6+ CD127- Tr1 cells suppress other CD4+ T cells through IL-10 and are associated with fewer symptoms but delayed parasite clearance (PMID 42084919). With Dr. Ashraful Haque of the University of Melbourne, we are studying how repeated infection shapes T cell responses in children and mice.
In pregnancy, we found that Plasmodium-specific Tr1 cells were highly prevalent in primigravid women and associated with a higher risk of malaria in pregnancy (PMID 37634385). Gravidity-dependent protection against placental malaria was associated with enhanced NK cell-mediated antibody-dependent cellular activation driven by Fc-afucosylated VAR2CSA-specific antibodies (PMID 42660020). We are now studying the placental immune environment using spatial transcriptomics and multiplexed ion beam imaging.
Finally, we are evaluating artemisinin-based chemoprevention in children and pregnant women and how it alters the development of protective immunity. In a preliminary trial, chemoprevention in infancy appeared to enhance subsequent immunity to malaria (PMID 31307883). In the Phase 3 MIC-DroP trial (NCT04978272), 924 Ugandan infants were randomized to monthly dihydroartemisinin-piperaquine or placebo from 8 weeks to 2 years of age and are being followed to 4 years. We are testing whether preventing malaria in infancy enhances protective immunity by limiting malaria-induced immunoregulation. We will soon begin enrolling PMC-VAC, a Phase 3 trial in which 1,290 Ugandan infants receiving the R21/Matrix-M vaccine will be randomized to perennial malaria chemoprevention with dihydroartemisinin-piperaquine, sulfadoxine-pyrimethamine plus amodiaquine, or placebo.